Completed PHASE2 INTERVENTIONAL 2-arm NCT04065139

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study (PIPAC EstoK 01)

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study - PIPAC EstoK 01

Sponsor: Assistance Publique - Hôpitaux de Paris

Conditions Cancer Metastatic Chemotherapy Effect Gastric Adenocarcinoma

Interventions Pressurized intraperitoneal aerosol chemotherapy (PIPAC) Standard chemotherapy

Updated 7 times since 2019 Last updated: Sep 13, 2024 Started: Jun 11, 2020 Primary completion: Mar 2, 2024 Completion: Mar 2, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cancer Metastatic and Chemotherapy Effect, this trial is completed. The trial is conducted by Assistance Publique - Hôpitaux de Paris and has accumulated 7 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Oct 2024 — Present [monthly]

Completed PHASE2

Status: Suspended → Completed
Sep 2024 — Oct 2024 [monthly]

Suspended PHASE2
Jul 2024 — Sep 2024 [monthly]

Suspended PHASE2
Jan 2023 — Jul 2024 [monthly]

Suspended PHASE2
Sep 2022 — Jan 2023 [monthly]

Suspended PHASE2

Status: Not Yet Recruiting → Suspended

▶ Show 2 earlier versions

Jan 2021 — Sep 2022 [monthly]

Not Yet Recruiting PHASE2
Sep 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assistance Publique - Hôpitaux de Paris

Data source: Assistance Publique - Hôpitaux de Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lille, France